39191-07-6

Basic information

• Product Name: 3-CHLORO-N-METHYLBENZYLAMINE
• Synonyms: 3-CHLORO-N-METHYLBENZYLAMINE;M-CHLORO-N-METHYLBENZYLAMINE;N-(3-CHLOROBENZYL)-N-METHYLAMINE;3-Chloro-N-methylbenzenemethanamine;N-Methyl-3-chlorobenzylamine;3-Chloro-N-methylbenzylamine ,97%;3-CHLORO-N-METHYLBEN;N-(3-Chlorobenzyl)-N-methylamine, Tech.
• CAS NO: 39191-07-6
• Molecular Formula: C₈H₁₀ClN
• Molecular Weight: 155.62
• EINECS: 254-343-8
• Product Categories: Polyamines;Amines;C8;Nitrogen Compounds
• Mol File: 39191-07-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 97 °C0.6 mm Hg(lit.)
• Flash Point: 115 °F
• Appearance: colorless liquid.
• Density: 1.072 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.232mmHg at 25°C
• Refractive Index: n20/D 1.5395(lit.)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.34±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-CHLORO-N-METHYLBENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-N-METHYLBENZYLAMINE(39191-07-6)
• EPA Substance Registry System: 3-CHLORO-N-METHYLBENZYLAMINE(39191-07-6)

Safety Data

• Hazard Codes: Xn
• Statements: 10-22-38-41
• Safety Statements: 16-26-36/37/39
• RIDADR: UN 1993 3/PG 1
• WGK Germany: 2
• TSCA: Yes
• HazardClass: 3
• PackingGroup: Ⅲ
• Hazardous Substances Data: 39191-07-6(Hazardous Substances Data)

Usage

General Description

3-Chloro-N-methylbenzylamine is an organic compound with the chemical formula C8H10ClN. It is a clear to pale yellow liquid with a pungent odor. This chemical is commonly used as an intermediate for the synthesis of pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis for the preparation of various compounds. 3-Chloro-N-methylbenzylamine is considered to be a hazardous substance, as it can cause irritation to the skin, eyes, and respiratory system upon contact or inhalation. Proper safety precautions should be taken when handling this chemical, and it should be stored and disposed of according to relevant regulations.

InChI:InChI=1/C8H10ClN/c1-10-6-7-3-2-4-8(9)5-7/h2-5,10H,6H2,1H3/p+1

Upstream product

• 67-56-1 methanol 
• 126799-85-7 3-chlorobenzylazide 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 
• 587-04-2 m-Chlorobenzaldehyde 
• 620-20-2 1-Chloro-3-chloromethyl-benzene 
• 90434-25-6 1-(3-chlorophenyl)-N-methylmethanimine 
• 766-80-3 1-bromomethyl-3-chlorobenzene 

Downstream Products

• 876476-09-4 (3-bromo-benzyl)-(3-chloro-benzyl)-methyl-amine 
• 854392-02-2 (3-chloro-benzyl)-methyl-(4-nitro-benzyl)-amine 
• 112534-56-2 N-(3-chloro-benzyl)-N-methyl-glycine nitrile 
• 876476-05-0 (4-bromo-benzyl)-(3-chloro-benzyl)-methyl-amine 
• 93683-68-2 6-[(3-Chloro-benzyl)-methyl-amino]-3-nitro-pyridine-2-carbonitrile 
• 80077-73-2 C₁₂H₁₄ClN₅S 
• 79140-38-8 C₁₁H₁₄ClN₅O₂S 
• 98736-46-0 N-Nitroso-N-methyl-m-chlorbenzylamin 
• 93683-81-9 3-Amino-6-[(3-chloro-benzyl)-methyl-amino]-pyridine-2-carbonitrile 
• 93683-93-3 N⁶-(3-Chloro-benzyl)-N⁶-methyl-pyrido[3,2-d]pyrimidine-2,4,6-triamine 
• 59709-66-9 (3-chloro-benzyl)-methyl-carbamonitrile 
• 103264-69-3 N-(3-chloro-benzyl)-N-methyl-ethylenediamine 
• 957112-98-0 C₃₄H₄₃ClFN₃O₆ 
• 1092060-48-4 C₂₅H₂₄ClFN₂ 

Relevant articles and documents

Selective synthesis of mono- and di-methylated amines using methanol and sodium azide as C1 and N1 sources

A Ru(ii) complex mediated synthesis of various N,N-dimethyl and N-monomethyl amines from organic azides using methanol as a methylating agent is reported. This methodology was successfully applied for a one-pot reaction of bromide derivatives and sodium azide in methanol. Notably, by controlling the reaction time several N-monomethylated and N,N-dimethylated amines were synthesized selectively. The practical applicability of this tandem process was revealed by preparative scale reactions with different organic azides and synthesis of an anti-vertigo drug betahistine. Several kinetic experiments and DFT studies were carried out to understand the mechanism of this transformation.

Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome

On the basis of its essential role in driving inflammation and disease pathology, cell necrosis has gradually been verified as a promising therapeutic target for treating atherosclerosis, systemic inflammatory response syndrome (SIRS), and ischemia injury, among other diseases. Most necrosis inhibitors targeting receptor-interacting protein 1 (RIP1) still require further optimization because of weak potency or poor metabolic stability. We conducted a phenotypic screen and identified a micromolar hit with novel amide structure. Medicinal chemistry efforts yielded a highly potent, selective, and metabolically stable drug candidate, compound 56 (RIPA-56). Biochemical studies and molecular docking revealed that RIP1 is the direct target of this new series of type III kinase inhibitors. In the SIRS mice disease model, 56 efficiently reduced tumor necrosis factor alpha (TNFα)-induced mortality and multiorgan damage. Compared to known RIP1 inhibitors, 56 is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model studies.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.